TY - JOUR
T1 - Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma
AU - Hoshino, Yoshinori
AU - Hasegawa, Hirotoshi
AU - Ishii, Yoshiyuki
AU - Endo, Takashi
AU - Ochiai, Hiroki
AU - Okabayashi, Koji
AU - Kaneko, Gou
AU - Mikami, Shuji
AU - Mukai, Makio
AU - Oya, Mototsugu
AU - Kitagawa, Yuko
PY - 2012/8
Y1 - 2012/8
N2 - Sunitinib, a multitargeted tyrosine kinase inhibitor, is widely used in the treatment of carcinoma. Adverse events associated with this treatment, including fatigue, diarrhea, and hematotoxicity, have been reported in clinical trials.Bowel perforation is a surgical emergency that requires immediate treatment depending on the location and progression of the tumor. We report 2 cases of bowel perforation during sunitinib treatment. The patients presented with diffuse peritonitis, and emergency exploratory laparotomy was performed. We speculate that the underlying mechanisms were decrease in capillary density of the normal mucosa in case 1 and tumor shrinkage because of sunitinib treatment in case 2. To the best of our knowledge, this is the first study to report the pathological findings implicating bowel perforation due to sunitinib treatment. Further investigations are needed to clarify the risk factors for intestinal perforations associated with sunitinib treatment.
AB - Sunitinib, a multitargeted tyrosine kinase inhibitor, is widely used in the treatment of carcinoma. Adverse events associated with this treatment, including fatigue, diarrhea, and hematotoxicity, have been reported in clinical trials.Bowel perforation is a surgical emergency that requires immediate treatment depending on the location and progression of the tumor. We report 2 cases of bowel perforation during sunitinib treatment. The patients presented with diffuse peritonitis, and emergency exploratory laparotomy was performed. We speculate that the underlying mechanisms were decrease in capillary density of the normal mucosa in case 1 and tumor shrinkage because of sunitinib treatment in case 2. To the best of our knowledge, this is the first study to report the pathological findings implicating bowel perforation due to sunitinib treatment. Further investigations are needed to clarify the risk factors for intestinal perforations associated with sunitinib treatment.
KW - Emergency surgery
KW - Perforation
KW - Renal cell carcinoma
KW - Sunitinib
UR - http://www.scopus.com/inward/record.url?scp=84867332744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867332744&partnerID=8YFLogxK
U2 - 10.1007/s10147-011-0318-z
DO - 10.1007/s10147-011-0318-z
M3 - Article
C2 - 21927829
AN - SCOPUS:84867332744
SN - 1341-9625
VL - 17
SP - 412
EP - 416
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 4
ER -
